Furthermore, ER-α66 (wild-type) and ER-α36 (splicing variant) were expressed inversely in non-tumor, non-cirrhotic to cirrhotic and cancerous stages [42], which enabled ER-α wild-type or variant transcripts in the tumor to be a better staging system for discriminating HCC prognosis than other scoring systems [43]. This evidence concerns the gene ESR1 and hepatocellular carcinoma.